Galantamine: Therapeutic effects beyond cognition

Dementia and Geriatric Cognitive Disorders

Volumn 11, Issue SUPPL. 1, 2000, Pages 28-34

  Blesa, Rafael ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Activities of daily living; Alzheimer's disease; Caregiver time; Dementia; Disability Assessment for Dementia; Galantamine; Outcome measures; Pittsburgh Sleep Quality Index; Sleep

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE; NICOTINIC RECEPTOR; PLACEBO;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; CAREGIVER; COGNITION; DAILY LIFE ACTIVITY; DEMENTIA; DRUG EFFICACY; FUNCTIONAL ASSESSMENT; HUMAN; MEMORY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SLEEP;

EID: 0033814116     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051229     Document Type: Review

References (44)

1. WHO: International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). Geneva: World Health Organization, 1992.
2. American Psychiatric Association (APA): Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, APA, 1994.
3. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
4. Brodaty H, Lie D: Symptomatology: Functional capacity and behaviour; in Wimo A, Karlsson G, Winblad B (eds): Health Economics of Dementia. Chichester, John Wiley & Sons Ltd., 1998, pp 33-51.
5. Haley WE, Levine EG, Brown SL, Berry JW, Hughes GH: Psychological, social, and health consequences of caring for a relative with senile dementia. J Am Geriatr Soc 1987;35:405-411.
6. Bartus RT, Dean RL 3rd, Beer B, Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-414.
7. Cummings JL, Back C: The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry 1998;6(2suppl 1):S64-S78.
8. Feldman H, Gracon S: Alzheimer's disease: Symptomatic drugs under development; in Gauthier S (ed): Clinical Diagnosis and Management of Alzheimer's Disease. London, Martin Dunitz Ltd, 1996.
9. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR: Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 1982;215:1237-1239.
10. Coyle JT, Price DL, DeLong MR: Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 1983;219:1184-1190.
11. Giacobini E: The cholinergic system in Alzheimer disease. Prog Brain Res 1990;84:321-332.
12. Levy R: Is there life in the neurotransmitter approach to the treatment of Alzheimer's disease?; in Levy R, Howard R, Burns A (eds): Treatment and Care in Old Age Psychiatry. Petersfield, Wrightson Biomedical Publishing Ltd., 1993, pp 39-46.
13. Schneider LS: New therapeutic approaches to Alzheimer's disease. J Clin Psychiatry 1996;57 (suppl 14):30-36.
14. Albuquerque EX, Alkondon M, Pereira EF, Castro NG, Schrattenholz A, Barbosa CT, Bonfante-Cabarcas R, Aracava Y, Eisenberg HM, Maelicke A: Properties of neuronal nicotinic acetylcholine receptors: Pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther 1997;280:1117-1136.
15. Bores GM, Huger FP, Petko W, Mutlib AE, Camacho F, Rush DK, Selk DE, Wolf V, Kosley RW Jr, Davis L, Vargas HM: Pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 1996;277:728-738.
16. Lawrence AD, Sahakian BJ: The cognitive psychopharmacology of Alzheimer's disease: Focus on cholinergic systems. Neurochem Res 1998;23:787-794.
17. Borison RL: Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 1995;15(suppl 1): 24S-29S.
18. Stahl SM: Are two antidepressant mechanisms better than one? J Clin Psychiatry 1997;58: 339-340.
19. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Parys W, Ding C and the Galantamine USA-10 Study Group: A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269-2276.
20. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal LJ, and the Alzheimer's Disease Cooperative Study: Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer's Disease Assessment Scale that broadens its scope. Alzheimer Dis Assoc Disord 1997;11(suppl2):S13-S21.
21. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
22. Rogers SL, Friedhoff LT: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998; 8:67-75.
23. Imbimbo BP, Verdelli G, Martelli P, Marchesini D, and the Eptastigmine Study Group: Two-year treatment of Alzheimer's disease with eptastigmine. Dement Geriatr Cogn Disord 1999;10:139-147.
24. Raskind M, Peskind E, Wessel T, Parys W, Yuan W and the Galantamine USA-1 Study Group: Galantamine in AD - a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261-2268.
25. Gélinas I, Auer S: Functional autonomy; in Gauthier S (ed): Clinical Diagnosis and Management of Alzheimer's Disease. London, Martin Dunitz Ltd, 1996, pp 191-202.
26. Gauthier S, Gélinas I, Gauthier L: Functional disability in Alzheimer's disease. Int Psychogeriatr 1997;9(suppl 1):163-165.
27. Gélinas I, Gauthier L, McIntyre M, Gauthier S: Development of a functional measure for persons with Alzheimer's disease: The disability assessment for dementia. Am J Occup Ther 1999;53:471-481.
28. Wilkinson D, Lilienfeld S, Truyen L: Galantamine improves activities of daily living in patients with Alzheimer's disease: A 3-month placebo-controlled study. Poster presented at the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, Stockholm, Sweden, April 5-8, 2000.
29. Rogers SL, Friedhoff LT: The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293-303.
30. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman N, Ferris S, and the Alzheimer's Disease Cooperative Study: An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S33-S39.
31. Torfs K, Feldman H, on behalf of the Sabeluzole Study Groups: 12-month decline in cognitive and daily function in patients with mild-to-moderate Alzheimer's disease: Two randomized, placebo-controlled studies. Poster presented at World Alzheimer Congress, Washington, DC, USA, July 9-13, 2000.
32. Mohs RC, Ferris SH: Measuring response to treatment in Alzheimer's disease: What constitutes meaningful change? Int J Geriatr Psychopharmacol 1998;1(suppl 1):S7-S14.
33. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
34. Clipp EC, Moore MJ: Caregiver time use: An outcome measure in clinical trial research on Alzheimer's disease. Clin Pharmacol Ther 1995;58:228-236.
35. Donaldson C, Tarrier N, Burns A: The impact of the symptoms of dementia on caregivers. Br J Psychiatry 1997;170:62-68.
36. Davis KL, Marin DB, Kane R, Patrick D, Peskind ER, Raskind MA, Puder KL: The Caregiver Activity Survey (CAS): Development and validation of a new measure for caregivers of persons with Alzheimer's disease. Int J Geriatr Psychiatry 1997;12:978-988.
37. Wimo A, Gustafsson L, Mattson B: Predictive validity of factors influencing the institutionalization of elderly people with psychogeriatric disorders. Scand J Prim Health Care 1992;10: 185-191.
38. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, Rogers SL, Friedhoff LT: The effects of donepezil in Alzheimer's disease -results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-244.
39. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, and the Donepezil Study Group: Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998;158:1021-1031.
40. Jenkins CD, Stanton BA, Niemcryk SJ, Rose RM: A scale for the estimation of sleep problems in clinical research. J Clin Epidemiol 1988;41:313-321.
41. Parrott AC, Hindmarch I: The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations - a review. Psychopharmacology 1980;71:173-179.
42. Ellis BW, Johns MW, Lancaster R, Raptopoulos P, Angelopoulos N, Priest RG: The St. Mary's Hospital Sleep Questionnaire: A study of reliability. Sleep 1981;4:93-97.
43. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res 1989; 28:193-213.
44. Rockwood K, Kershaw P, on behalf of the Galantamine International-2 Study Group: Galantamine's clinical benefits are not offset by sleep disturbance: A 3-month placebo-controlled study in patients with Alzheimer's disease. Poster presented at World Alzheimer Congress, Washington, DC, USA, July 9-13, 2000.